JASON OSEI MENSAH
- Type
- Physician · Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry
- Where
- BEAUMONT, TX
- NPI
- 1619137593
- Received
- $460,437 in 1,041 records, 2019 to 2025 ($207,659 general, $252,777 research)
- As principal investigator
- $10,046,130 of research payments to others in 173 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 196 | $24,059 |
| 2024 | General payment | 168 | $35,046 |
| 2023 | General payment | 173 | $54,403 |
| 2023 | Research payment | 2 | $6,845 |
| 2022 | General payment | 129 | $28,312 |
| 2022 | Research payment | 2 | $21,381 |
| 2021 | General payment | 163 | $36,662 |
| 2021 | Research payment | 2 | $224,551 |
| 2020 | General payment | 129 | $10,877 |
| 2019 | General payment | 77 | $18,298 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 6 | $252,777 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 70 | $137,715 |
| Consulting Fee | 8 | $25,805 |
| Food and Beverage | 918 | $18,975 |
| Honoraria | 4 | $14,375 |
| Travel and Lodging | 27 | $10,344 |
| Education | 8 | $444 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-18 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-17 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-12-16 | Corium, LLC | $25 | Food and Beverage | In-kind items and services | Azstarys Drug, CNS Stimulant for ADHD | 2025 | |
| 2025-12-16 | Axsome Therapeutics, Inc. | $24 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-12-16 | Corium, LLC | $2 | Food and Beverage | In-kind items and services | Azstarys Drug, CNS Stimulant for ADHD | 2025 | |
| 2025-12-15 | Teva Pharmaceuticals USA, Inc. | $5 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-12-11 | Lundbeck LLC | $21 | Food and Beverage | Cash or cash equivalent | ABILIFY ASIMTUFII Drug, PSYCHIATRY | 2025 | |
| 2025-12-09 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-09 | Neurocrine BioSciences, Inc. | $16 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-12-08 | Tris Pharma Inc | $15 | Food and Beverage | In-kind items and services | Dyanavel XR Drug, ADHD | 2025 | |
| 2025-12-08 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-12-08 | Teva Pharmaceuticals USA, Inc. | $10 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-12-05 | Vanda Pharmaceuticals Inc. | $21 | Food and Beverage | In-kind items and services | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-12-04 | Corium, LLC | $12 | Food and Beverage | In-kind items and services | Azstarys Drug, CNS Stimulant for ADHD | 2025 | |
| 2025-12-04 | Corium, LLC | $7 | Food and Beverage | In-kind items and services | Azstarys Drug, CNS Stimulant for ADHD | 2025 | |
| 2025-12-04 | Corium, LLC | $3 | Food and Beverage | In-kind items and services | Azstarys Drug, CNS Stimulant for ADHD | 2025 | |
| 2025-12-04 | Corium, LLC | $2 | Food and Beverage | In-kind items and services | Azstarys Drug, CNS Stimulant for ADHD | 2025 | |
| 2025-12-03 | Alkermes, Inc. | $20 | Food and Beverage | In-kind items and services | ARISTADA Drug, CNS | 2025 | |
| 2025-12-02 | E.R. Squibb & Sons, L.L.C. | $14 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-11-20 | Validus Pharmaceuticals LLC | $15 | Food and Beverage | Cash or cash equivalent | RALDESY Drug, CNS | 2025 | |
| 2025-11-20 | Otsuka America Pharmaceutical, Inc. | $6 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-11-19 | Axsome Therapeutics, Inc. | $16 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-11-19 | Corium, LLC | $15 | Food and Beverage | In-kind items and services | Azstarys Drug, CNS Stimulant for ADHD | 2025 | |
| 2025-11-19 | Teva Pharmaceuticals USA, Inc. | $10 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-11-19 | Corium, LLC | $9 | Food and Beverage | In-kind items and services | Azstarys Drug, CNS Stimulant for ADHD | 2025 | |
| 2025-11-18 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-11-18 | Tris Pharma Inc | $14 | Food and Beverage | In-kind items and services | Dyanavel XR Drug, ADHD | 2025 | |
| 2025-11-17 | Otsuka America Pharmaceutical, Inc. | $17 | Food and Beverage | In-kind items and services | ABILIFY ASIMTUFII Drug, PSYCHIATRY | 2025 | |
| 2025-11-14 | Neos Therapeutics, LP | $18 | Food and Beverage | Cash or cash equivalent | Adzenys XR-ODT Drug, ADHD | 2025 | |
| 2025-11-11 | Lundbeck LLC | $23 | Food and Beverage | Cash or cash equivalent | ABILIFY ASIMTUFII Drug, PSYCHIATRY | 2025 | |
| 2025-11-11 | Axsome Therapeutics, Inc. | $12 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-11-06 | Neurocrine BioSciences, Inc. | $24 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-11-05 | Corium, LLC | $24 | Food and Beverage | In-kind items and services | Azstarys Drug, CNS Stimulant for ADHD | 2025 | |
| 2025-11-05 | Corium, LLC | $6 | Food and Beverage | In-kind items and services | Azstarys Drug, CNS Stimulant for ADHD | 2025 | |
| 2025-11-05 | Corium, LLC | $6 | Food and Beverage | In-kind items and services | Azstarys Drug, CNS Stimulant for ADHD | 2025 | |
| 2025-11-03 | Teva Pharmaceuticals USA, Inc. | $21 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-11-03 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-30 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-29 | Otsuka America Pharmaceutical, Inc. | $23 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-10-28 | Alkermes, Inc. | $16 | Food and Beverage | In-kind items and services | ARISTADA Drug, CNS | 2025 | |
| 2025-10-28 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-28 | Corium, LLC | $12 | Food and Beverage | In-kind items and services | Azstarys Drug, CNS Stimulant for ADHD | 2025 | |
| 2025-10-25 | Neos Therapeutics, LP | $17 | Food and Beverage | Cash or cash equivalent | Adzenys XR-ODT Drug, ADHD | 2025 | |
| 2025-10-23 | Corium, LLC | $14 | Food and Beverage | In-kind items and services | Azstarys Drug, CNS Stimulant for ADHD | 2025 | |
| 2025-10-23 | Corium, LLC | $2 | Food and Beverage | In-kind items and services | Azstarys Drug, CNS Stimulant for ADHD | 2025 | |
| 2025-10-22 | Vanda Pharmaceuticals Inc. | $19 | Food and Beverage | In-kind items and services | HETLIOZ Drug, NON-24-HOUR SLEEP-WAKE DISORDER | 2025 | |
| 2025-10-22 | Vanda Pharmaceuticals Inc. | $17 | Food and Beverage | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-21 | Neurocrine BioSciences, Inc. | $24 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-10-21 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-21 | Teva Pharmaceuticals USA, Inc. | $12 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-10-17 | Janssen Pharmaceuticals, Inc | $16 | Food and Beverage | In-kind items and services | INVEGA SUSTENNA Drug, Neuroscience | 2025 | |
| 2025-10-15 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $23 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-15 | Corium, LLC | $11 | Food and Beverage | In-kind items and services | Azstarys Drug, CNS Stimulant for ADHD | 2025 | |
| 2025-10-13 | Corium, LLC | $18 | Food and Beverage | In-kind items and services | Azstarys Drug, CNS Stimulant for ADHD | 2025 | |
| 2025-10-13 | Corium, LLC | $6 | Food and Beverage | In-kind items and services | Azstarys Drug, CNS Stimulant for ADHD | 2025 | |
| 2025-10-09 | Corium, LLC | $8 | Food and Beverage | In-kind items and services | Azstarys Drug, CNS Stimulant for ADHD | 2025 | |
| 2025-10-09 | Corium, LLC | $4 | Food and Beverage | In-kind items and services | Azstarys Drug, CNS Stimulant for ADHD | 2025 | |
| 2025-10-08 | Vanda Pharmaceuticals Inc. | $19 | Food and Beverage | In-kind items and services | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-07 | Alkermes, Inc. | $21 | Food and Beverage | In-kind items and services | LYBALVI Drug, CNS | 2025 | |
| 2025-10-06 | Teva Pharmaceuticals USA, Inc. | $17 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-10-06 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $12 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-02 | Axsome Therapeutics, Inc. | $20 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-09-29 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-09-25 | Neurocrine BioSciences, Inc. | $27 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-25 | Neurocrine BioSciences, Inc. | $4 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-24 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-23 | IDORSIA PHARMACEUTICALS US INC | $25 | Food and Beverage | In-kind items and services | Quviviq Drug, Insomnia | 2025 | |
| 2025-09-23 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $23 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-09-18 | Teva Pharmaceuticals USA, Inc. | $21 | Food and Beverage | In-kind items and services | UZEDY Drug, Neurology | 2025 | |
| 2025-09-17 | Tris Pharma Inc | $18 | Food and Beverage | In-kind items and services | Dyanavel XR Drug, ADHD | 2025 | |
| 2025-09-17 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-15 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $15 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-11 | Janssen Pharmaceuticals, Inc | $34 | Food and Beverage | In-kind items and services | INVEGA SUSTENNA Drug, Neuroscience | 2025 | |
| 2025-09-10 | Axsome Therapeutics, Inc. | $1,100 | Honoraria | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-09-10 | Lundbeck LLC | $16 | Food and Beverage | Cash or cash equivalent | ABILIFY ASIMTUFII Drug, PSYCHIATRY | 2025 | |
| 2025-09-04 | E.R. Squibb & Sons, L.L.C. | $16 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-09-02 | Teva Pharmaceuticals USA, Inc. | $18 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-08-29 | Teva Pharmaceuticals USA, Inc. | $10 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-08-28 | Otsuka America Pharmaceutical, Inc. | $5 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-08-28 | Teva Pharmaceuticals USA, Inc. | $3 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-08-27 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-08-26 | Otsuka America Pharmaceutical, Inc. | $12 | Food and Beverage | In-kind items and services | ABILIFY ASIMTUFII Drug, PSYCHIATRY | 2025 | |
| 2025-08-21 | Neos Therapeutics, LP | $15 | Food and Beverage | Cash or cash equivalent | Adzenys XR-ODT Drug, ADHD | 2025 | |
| 2025-08-18 | Teva Pharmaceuticals USA, Inc. | $20 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-08-14 | Neurocrine BioSciences, Inc. | $26 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-08-12 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $27 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-08-12 | Vanda Pharmaceuticals Inc. | $21 | Food and Beverage | In-kind items and services | HETLIOZ Drug, NON-24-HOUR SLEEP-WAKE DISORDER | 2025 | |
| 2025-08-11 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-08-07 | Axsome Therapeutics, Inc. | $29 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-08-07 | Otsuka America Pharmaceutical, Inc. | $7 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-08-06 | ABBVIE INC. | $2,875 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-08-06 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-08-05 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-08-01 | Otsuka America Pharmaceutical, Inc. | $17 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-07-28 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-07-21 | Teva Pharmaceuticals USA, Inc. | $21 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-07-17 | Vanda Pharmaceuticals Inc. | $34 | Food and Beverage | In-kind items and services | HETLIOZ Drug, NON-24-HOUR SLEEP-WAKE DISORDER | 2025 | |
| 2025-07-17 | Teva Pharmaceuticals USA, Inc. | $22 | Food and Beverage | In-kind items and services | UZEDY Drug, Neurology | 2025 | |
| 2025-07-16 | Otsuka America Pharmaceutical, Inc. | $14 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-07-15 | Teva Pharmaceuticals USA, Inc. | $3 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-07-14 | Janssen Pharmaceuticals, Inc | $33 | Food and Beverage | In-kind items and services | INVEGA SUSTENNA Drug, Neuroscience | 2025 | |
| 2025-07-10 | E.R. Squibb & Sons, L.L.C. | $28 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-07-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | $25 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-08 | Otsuka America Pharmaceutical, Inc. | $20 | Food and Beverage | In-kind items and services | ABILIFY ASIMTUFII Drug, PSYCHIATRY | 2025 | |
| 2025-07-03 | Axsome Therapeutics, Inc. | $26 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-06-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | $203 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-06-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | $111 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | $42 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | $42 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | $21 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | $21 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-26 | Otsuka America Pharmaceutical, Inc. | $18 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-06-24 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $31 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-06-24 | Otsuka America Pharmaceutical, Inc. | $10 | Food and Beverage | In-kind items and services | ABILIFY ASIMTUFII Drug, PSYCHIATRY | 2025 | |
| 2025-06-23 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-06-23 | Axsome Therapeutics, Inc. | $11 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-06-10 | Lundbeck LLC | $31 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-06-09 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-06-06 | Otsuka America Pharmaceutical, Inc. | $14 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-06-05 | Neurocrine BioSciences, Inc. | $86 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-06-05 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $23 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-06-05 | Teva Pharmaceuticals USA, Inc. | $16 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-06-04 | Otsuka America Pharmaceutical, Inc. | $14 | Food and Beverage | In-kind items and services | ABILIFY ASIMTUFII Drug, PSYCHIATRY | 2025 | |
| 2025-06-04 | Otsuka America Pharmaceutical, Inc. | $1 | Food and Beverage | In-kind items and services | ABILIFY ASIMTUFII Drug, PSYCHIATRY | 2025 | |
| 2025-06-03 | Neurocrine BioSciences, Inc. | $19 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-05-31 | Axsome Therapeutics, Inc. | $24 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-05-28 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-05-22 | Neurocrine BioSciences, Inc. | $160 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-05-20 | Neurocrine BioSciences, Inc. | $27 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-05-18 | Neurocrine BioSciences, Inc. | $37 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-05-13 | Neurocrine BioSciences, Inc. | $24 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-05-13 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-05-12 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-05-09 | Janssen Pharmaceuticals, Inc | $24 | Food and Beverage | In-kind items and services | SPRAVATO Drug, Neuroscience | 2025 | |
| 2025-05-09 | Axsome Therapeutics, Inc. | $18 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-05-07 | Boehringer Ingelheim Pharmaceuticals, Inc. | $386 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-05-07 | Neurocrine BioSciences, Inc. | $20 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-05-06 | Lundbeck LLC | $34 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-04-30 | Teva Pharmaceuticals USA, Inc. | $21 | Food and Beverage | In-kind items and services | UZEDY Drug, Neurology | 2025 | |
| 2025-04-29 | Alkermes, Inc. | $17 | Food and Beverage | In-kind items and services | LYBALVI Drug, CNS | 2025 | |
| 2025-04-24 | Otsuka America Pharmaceutical, Inc. | $5 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-04-24 | Otsuka America Pharmaceutical, Inc. | $0 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-04-22 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-04-22 | Lundbeck LLC | $9 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-04-21 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-04-16 | Axsome Therapeutics, Inc. | $19 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-04-15 | Axsome Therapeutics, Inc. | $1,650 | Honoraria | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-04-15 | Teva Pharmaceuticals USA, Inc. | $101 | Education | In-kind items and services | 2025 | ||
| 2025-04-15 | Neurocrine BioSciences, Inc. | $30 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-04-10 | Janssen Pharmaceuticals, Inc | $31 | Food and Beverage | In-kind items and services | SPRAVATO Drug, Neuroscience | 2025 | |
| 2025-04-09 | Neurocrine BioSciences, Inc. | $27 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-04-09 | Lundbeck LLC | $23 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-04-08 | Neurocrine BioSciences, Inc. | $25 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-04-04 | Teva Pharmaceuticals USA, Inc. | $11 | Food and Beverage | In-kind items and services | UZEDY Drug, Neurology | 2025 | |
| 2025-04-03 | Axsome Therapeutics, Inc. | $9,350 | Honoraria | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-04-02 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $24 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-03-27 | Otsuka America Pharmaceutical, Inc. | $15 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-03-27 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-03-26 | Janssen Pharmaceuticals, Inc | $27 | Food and Beverage | In-kind items and services | INVEGA SUSTENNA Drug, Neuroscience | 2025 | |
| 2025-03-25 | Lundbeck LLC | $8 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-03-24 | Alkermes, Inc. | $14 | Food and Beverage | In-kind items and services | LYBALVI Drug, CNS | 2025 | |
| 2025-03-19 | Tris Pharma Inc | $16 | Food and Beverage | In-kind items and services | Dyanavel XR Drug, ADHD | 2025 | |
| 2025-03-18 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-03-17 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-03-15 | Axsome Therapeutics, Inc. | $1,091 | Travel and Lodging | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-03-15 | Axsome Therapeutics, Inc. | $469 | Travel and Lodging | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-03-15 | Axsome Therapeutics, Inc. | $125 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-03-15 | Axsome Therapeutics, Inc. | $78 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-03-15 | Axsome Therapeutics, Inc. | $60 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-03-15 | Axsome Therapeutics, Inc. | $48 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-03-15 | Axsome Therapeutics, Inc. | $45 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-03-15 | Axsome Therapeutics, Inc. | $32 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-03-15 | Axsome Therapeutics, Inc. | $29 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-03-15 | Axsome Therapeutics, Inc. | $26 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-03-14 | Supernus Pharmaceuticals, Inc. | $15 | Food and Beverage | In-kind items and services | Qelbree Drug, VILOXAZINE HYDROCHLORIDE | 2025 | |
| 2025-03-07 | Teva Pharmaceuticals USA, Inc. | $17 | Food and Beverage | In-kind items and services | UZEDY Drug, Neurology | 2025 | |
| 2025-03-05 | Otsuka America Pharmaceutical, Inc. | $16 | Food and Beverage | In-kind items and services | ABILIFY ASIMTUFII Drug, PSYCHIATRY | 2025 | |
| 2025-03-04 | ABBVIE INC. | $2,875 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-02-27 | Janssen Pharmaceuticals, Inc | $40 | Food and Beverage | In-kind items and services | SPRAVATO Drug, Neuroscience | 2025 | |
| 2025-02-24 | Alkermes, Inc. | $19 | Food and Beverage | In-kind items and services | LYBALVI Drug, CNS | 2025 | |
| 2025-02-20 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-02-19 | Otsuka America Pharmaceutical, Inc. | $21 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-02-18 | ABBVIE INC. | $27 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-02-18 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-02-17 | Axsome Therapeutics, Inc. | $16 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-02-14 | Otsuka America Pharmaceutical, Inc. | $22 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-02-10 | E.R. Squibb & Sons, L.L.C. | $19 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-02-05 | ABBVIE INC. | $25 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-02-03 | Axsome Therapeutics, Inc. | $9 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-01-29 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-01-23 | Otsuka America Pharmaceutical, Inc. | $7 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-01-17 | Neurocrine BioSciences, Inc. | $32 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-01-16 | E.R. Squibb & Sons, L.L.C. | $16 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-01-14 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-01-09 | Teva Pharmaceuticals USA, Inc. | $22 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-01-03 | Neurocrine BioSciences, Inc. | $34 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2024-12-19 | Axsome Therapeutics, Inc. | $32 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2024 | |
| 2024-12-19 | Vanda Pharmaceuticals Inc. | $29 | Food and Beverage | In-kind items and services | HETLIOZ Drug, NON-24-HOUR SLEEP-WAKE DISORDER | 2024 | |
| 2024-12-17 | Teva Pharmaceuticals USA, Inc. | $25 | Food and Beverage | In-kind items and services | Austedo XR Drug, Central Nervous System | 2024 | |
| 2024-12-13 | Otsuka America Pharmaceutical, Inc. | $17 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2024 |
The latest 200 records of 1,041.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-31 | ABBVIE INC. | GREAT LAKES MEDICAL RESEARCH LLC | $1,099 | A 6-week, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $1,339 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $350 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $100 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $300 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $1,284 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $300 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $100 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $1,339 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $1,284 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $400 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $1,339 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $300 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $1,339 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $100 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $1,339 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $1,284 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $100 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $300 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $1,284 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $1,339 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $100 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $300 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $1,090 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $100 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $1,339 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $100 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $300 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $1,284 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $1,339 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $100 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $300 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $1,284 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $1,339 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $350 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $300 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $100 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $300 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $1,284 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-11-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $1,090 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-10-02 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $100 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-10-02 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $300 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-10-02 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $300 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-10-02 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $300 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-10-02 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $100 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-10-02 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $300 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-10-02 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $300 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-10-02 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $100 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-10-02 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $300 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-10-02 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $100 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-10-02 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $300 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-10-02 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $300 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-10-02 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $300 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-10-02 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $100 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-10-02 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $1,339 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-09-25 | ABBVIE INC. | THE CLINICAL TRIALS NETWORK LLC | $2,000 | A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatr | 2025 |
| 2025-09-23 | ABBVIE INC. | THE CLINICAL TRIALS NETWORK LLC | $2,000 | A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatr | 2025 |
| 2025-08-22 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $1,284 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-08-22 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $2,951 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-08-22 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $1,284 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-08-22 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $100 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-08-22 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $100 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-08-22 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $100 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-08-22 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $300 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-08-06 | ABBVIE INC. | THE CLINICAL TRIALS NETWORK LLC | $4,826 | A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatr | 2025 |
| 2025-08-01 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $4,999 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-07-28 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $1,284 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-07-28 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $100 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-07-28 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $100 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-07-28 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $350 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-07-28 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $1,284 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-07-28 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $1,284 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-07-28 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $1,284 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-07-28 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $1,284 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-07-28 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $2,951 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-07-28 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $2,951 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-07-02 | ABBVIE INC. | THE CLINICAL TRIALS NETWORK LLC | $15,227 | A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatr | 2025 |
| 2025-06-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $2,951 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-06-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $100 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-06-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $100 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-06-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $100 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-06-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $300 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-06-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $100 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-06-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $2,951 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-06-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $2,951 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-06-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $2,951 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-06-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $2,951 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-06-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $2,951 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-06-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $100 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-06-25 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $100 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-06-03 | ABBVIE INC. | THE CLINICAL TRIALS NETWORK LLC | $8,695 | A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatr | 2025 |
| 2025-05-27 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $100 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-05-27 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $2,951 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-05-07 | ABBVIE INC. | THE CLINICAL TRIALS NETWORK LLC | $750 | A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatr | 2025 |
| 2025-03-11 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $264 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-03-03 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $10,900 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-03-03 | Boehringer Ingelheim International GmbH | Beaumont Psychiatric Clinic-Jason Mensah DO PA | $750 | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital thera | 2025 |
| 2025-02-25 | Eli Lilly and Company | GADOLIN RESEARCH LLC | $93 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2025 |
| 2025-02-14 | ABBVIE INC. | THE CLINICAL TRIALS NETWORK LLC | $2,000 | A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatr | 2025 |
| 2025-02-10 | Eli Lilly and Company | GADOLIN RESEARCH LLC | $15,383 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2025 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Beaumont, TX, county Jefferson County, TX, state Texas; placed by its city name.
| Measure | Place (city or town) Beaumont, TX | County Jefferson County, TX | State Texas |
|---|---|---|---|
| Population B01003 | 113,279 | 253,878 | 30,188,424 |
| Population, 2020 census P1 | 115,282 | 256,526 | 29,145,505 |
| Median age B01002 | 35.3 | 37.0 | 35.6 |
| Under 18 B01001 | 25.3% | 24.6% | 25.0% |
| 65 and over B01001 | 16.3% | 15.5% | 13.4% |
| Households B11001 | 45,001 | 94,807 | 10,992,816 |
| Foreign born B05002 | 11.0% | 12.1% | 17.6% |
| Median household income B19013 | $56,997 | $60,026 | $78,476 |
| Median family income B19113 | $71,096 | $75,099 | $94,599 |
| Per capita income B19301 | $32,642 | $32,101 | $40,752 |
| Poverty rate B17001 | 21.2% | 19.5% | 13.8% |
| Unemployment rate B23025 | 6.4% | 6.3% | 5.3% |
| Civilian labor force B23025 | 52,630 | 110,898 | 15,233,563 |
| Mean commute (minutes) B08013 | 20.3 | 21.2 | 26.7 |
| Bachelor's degree or higher B15003 | 24.9% | 19.7% | 33.8% |
| Housing units B25001 | 52,439 | 109,884 | 12,128,515 |
| Owner-occupied B25003 | 55.3% | 62.5% | 62.6% |
| Renters B25003 | 44.7% | 37.5% | 37.4% |
| Median home value B25077 | $166,400 | $169,500 | $283,800 |
| Median gross rent B25064 | $1,121 | $1,117 | $1,403 |
| White, not Hispanic B03002 | 26.3% | 36.3% | 39.1% |
| Black B03002 | 45.2% | 32.7% | 11.9% |
| Hispanic or Latino B03002 | 20.8% | 24.1% | 39.7% |
| Asian B03002 | 3.8% | 3.8% | 5.5% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Beaumont, TX.
Comments